Detalhe da pesquisa
1.
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Future Oncol
; 20(12): 727-738, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38488039
2.
Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.
Urol Pract
; 11(1): 154-161, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914225
3.
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
JAMA Oncol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451492
4.
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Adv Ther
; 40(11): 4919-4927, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37713020
5.
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Front Oncol
; 13: 1289249, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37916156
6.
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Eur Urol Oncol
; 2023 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38143206